SCHEMBL21998157

SCHEMBL21998157

O=C(O)c1cc2nc(N3CCOC4(CCC4)C3)ccn2n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APOBEC3A P31941 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
LRRK2 Q5S007 3/20 0.33
FFAR2 O15552 5/20 0.33
KMO O15229 1/20 0.32
CFTR P13569 1/20 0.32
EIF2AK4 Q9P2K8 1/20 0.31
ALDH1A1 P00352 2/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
SYK P43405 1/20 0.31
MDM2 Q00987 1/20 0.30
KDM4E B2RXH2 1/20 0.30
USP2 O75604 1/20 0.30
LMNA P02545 1/20 0.30
GAA P10253 1/20 0.30
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30
TSHR P16473 1/20 0.30
CASP1 P29466 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25339860 0.96 APOBEC3A (0.38) APOBEC3AAPOBEC3GLRRK2FFAR2KMO
SCHEMBL21998253 0.85 PRKDC (0.42) APOBEC3AAPOBEC3GLRRK2FFAR2KMO
SCHEMBL25339272 0.85 APOBEC3A (0.38) APOBEC3AAPOBEC3GKMOALDH1A1L3MBTL1
SCHEMBL21996998 0.81 KMO (0.50) APOBEC3AAPOBEC3GKMOCFTRALDH1A1
SCHEMBL25338105 0.79 APOBEC3A (0.47) APOBEC3AAPOBEC3GALDH1A1SYKKDM4E
SCHEMBL25339261 0.79 APOBEC3A (0.47) APOBEC3AAPOBEC3GKMOALDH1A1SYK
SCHEMBL21998149 0.79 KMO (0.46) APOBEC3AAPOBEC3GKMOCFTRALDH1A1
SCHEMBL25337091 0.78 APOBEC3A (0.38) APOBEC3AAPOBEC3GALDH1A1SYKHPGD
SCHEMBL21996782 0.78 APOBEC3A (0.46) APOBEC3AAPOBEC3GALDH1A1L3MBTL1SYK
SCHEMBL21996887 0.77 IRAK4 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 US disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 US disclosed
EP-3886904-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-10-06 EP disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 US disclosed
WO-2020113233-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 APOBEC3A 219/4885APOBEC3G 151/4885LRRK2 606/4885
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 APOBEC3A 219/4885APOBEC3G 151/4885LRRK2 606/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 APOBEC3A 219/4885APOBEC3G 151/4885LRRK2 606/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 APOBEC3A 219/4885APOBEC3G 151/4885LRRK2 606/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 APOBEC3A 219/4885APOBEC3G 151/4885LRRK2 606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.